{"nctId":"NCT01544920","briefTitle":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","startDateStruct":{"date":"2012-05-30","type":"ACTUAL"},"conditions":["Hepatitis C, Chronic"],"count":737,"armGroups":[{"label":"Arm 1: peg-IFN + RBV","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: peg-Interferon alfa-2a","Drug: Ribavirin","Drug: Boceprevir"]},{"label":"Arm 2: BOC + peg-IFN + RBV","type":"EXPERIMENTAL","interventionNames":["Biological: peg-Interferon alfa-2a","Drug: Ribavirin","Drug: Boceprevir"]}],"interventions":[{"name":"peg-Interferon alfa-2a","otherNames":["Pegasys™; SCH 054031"]},{"name":"Ribavirin","otherNames":["Rebetol™; 018908"]},{"name":"Boceprevir","otherNames":["SCH 503034; Victrelis™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is ≥ 40 kg and ≤ 125 kg.\n* Documented CHC genotype 1 with HCV RNA ≥10,000 International Units (IU)/mL\n* Has IL-28B CC allele gene\n* Has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma (non-invasive fibroscan and Fibrotest can also be used for staging of liver disease).\n\nExclusion Criteria:\n\n* Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen \\[HBsAg\\] or HIV positive).\n* Previously treated with an interferon and ribavirin regimen or HCV direct acting antiviral regimen.\n* Treatment for hepatitis C with any investigational medication, or prior treatments with herbal remedies with known hepatotoxicity\n* Receiving any medication(s) within 2 weeks prior to the Day 1 visit that are highly dependent on Cytochrome P450 3A4 (CYP3A4/5) for clearance, and for which elevated plasma concentrations could be associated with serious and/or life-threatening events\n* Participation in any other clinical trial within 30 days of the screening visit in this trial or intention to participate in another clinical trial during participation in this trial.\n* Evidence of decompensated liver disease or hepatocellular carcinoma (HCC)\n* Is diabetic and/or hypertensive with significant retinopathy\n* Has any known medical condition that could interfere with the participation in and completion of the trial including immunologically-mediated disease, chronic pulmonary disease, or current or history of any clinically significant cardiac abnormalities/dysfunction.\n* Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years\n* Hemoglobin \\<12 g/dL for females and \\<13 g/dL for males\n* Neutrophils \\<1,500/mm\\^3, or \\<1,200/mm\\^3 for participants of African descent\n* Platelets \\<150,000/mm\\^3\n* Direct bilirubin \\>1.5 x upper limit of normal (ULN) of the laboratory reference range.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24)","description":"SVR24 rates were determined for all participants in Arm 1 and Arm 2. HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Had Undetectable HCV RNA at Week 4 Achieving SVR24","description":"SVR24 rates were determined for only participants that had undetectable HCV RNA at Week 4 of treatment (Arm 1a and Arm 2a). HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":368},"commonTop":["Anaemia","Pyrexia","Fatigue","Headache","Neutropenia"]}}}